MBG453
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 20 patients (estimated)
- Sponsors
- Massachusetts General Hospital
- Collaborators
- Novartis
- Tags
- Monoclonal Antibody, TIM-3
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1861
- NCT Identifier
- NCT04823624
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.